Integrative Proteomics Inc.
This article was originally published in Start Up
Executive Summary
Starting with linear amino acid sequence information, researchers are faced with the task of completing dossiers for particular proteins, filling in gaps in knowledge about their structures, their biochemical functions, and their physiological functions, to gain knowledge about what diseases or processes they regulate. Pharmaceutical and biotech companies know that this will ultimately result in drugs that interact with proteins to provide therapeutic benefits. The founders of Integrative Proteomics Inc. mean for this to happen sooner, rather than later. They have amassed a platform of protein-focused skills aimed at informing the drug discovery process at every step of the way, from target selection to lead optimization, and even at the marketing end, where proteomics could lead to population-customized drugs. The founders of IPI term their mission "pharmaceutical proteomics."
You may also be interested in...
The Proteomics Challenge
The fact that proteomic diversity is most likely several logs greater than genomic diversity is only one reason why moving from gene expression-based analyses to proteomics-based drug development presents a daunting challenge. The large issues go well beyond protein isolation and characterization: Genomics simply doesn't tell you how proteins function in vivo, and companies are just now beginning to amass and integrate the tools to correlate protein structure and function. In many ways, proteomics heralds the second coming of rational drug design, enabled now by high-throughput tools and the algorithms of computational biology. But whether structure-guided drug development will prove to be efficient or cost-effective remains to be seen.
Wound Solutions Ltd.
Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.
Patient-Centric Devices Promise Cost-Efficient Advanced Wound Care
The treatment of chronic wounds is challenging, not only because of the underlying biology, but also because of more practical considerations: fragmentation in the care settings, the logistics of delivering products to patients, and the costs of chronic care. Next generation advanced wound care companies are engineering solutions to these problems.